Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Operating Leases (2019 - 2023)

Insight Molecular Diagnostics' Operating Leases history spans 5 years, with the latest figure at $2.7 million for Q4 2023.

  • On a quarterly basis, Operating Leases changed 0.04% to $2.7 million in Q4 2023 year-over-year; TTM through Dec 2023 was $2.7 million, a 0.04% change, with the full-year FY2023 number at $2.7 million, changed 0.04% from a year prior.
  • Operating Leases hit $2.7 million in Q4 2023 for Insight Molecular Diagnostics, up from $2.6 million in the prior quarter.
  • Over the last five years, Operating Leases for IMDX hit a ceiling of $4.3 million in Q4 2020 and a floor of $2.6 million in Q1 2023.
  • Historically, Operating Leases has averaged $3.3 million across 5 years, with a median of $3.2 million in 2022.
  • Biggest five-year swings in Operating Leases: skyrocketed 61.14% in 2020 and later fell 23.33% in 2023.
  • Tracing IMDX's Operating Leases over 5 years: stood at $2.7 million in 2019, then soared by 61.14% to $4.3 million in 2020, then decreased by 17.79% to $3.5 million in 2021, then dropped by 23.02% to $2.7 million in 2022, then rose by 0.04% to $2.7 million in 2023.
  • Business Quant data shows Operating Leases for IMDX at $2.7 million in Q4 2023, $2.6 million in Q1 2023, and $2.7 million in Q4 2022.